At the time of writing, PTC Therapeutics Inc [PTCT] stock is trading at $25.49, up 1.11%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The PTCT shares have gain 3.24% over the last week, with a monthly amount drifted -8.83%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
PTC Therapeutics Inc [NASDAQ: PTCT] stock has seen the most recent analyst activity on December 19, 2023, when Morgan Stanley downgraded its rating to a Underweight but kept the price target unchanged to $28 for it. Previously, Wells Fargo started tracking the stock with Overweight rating on December 08, 2023, and set its price target to $37. On October 30, 2023, upgrade upgraded it’s rating to Outperform but maintained its price target of $165 on the stock. Citigroup downgraded its rating to a Sell and decreased its price target to $17 on October 27, 2023. Truist downgraded its rating to a Hold and reduced its price target to $25 on October 06, 2023. Citigroup downgraded its rating to Neutral for this stock on September 18, 2023, and downed its price target to $28. In a note dated September 15, 2023, Raymond James downgraded an Underperform rating on this stock.
For the past year, the stock price of PTC Therapeutics Inc fluctuated between $17.53 and $59.84. Currently, Wall Street analysts expect the stock to reach $47.25 within the next 12 months. PTC Therapeutics Inc [NASDAQ: PTCT] shares were valued at $25.49 at the most recent close of the market. An investor can expect a potential return of 85.37% based on the average PTCT price forecast.
Analyzing the PTCT fundamentals
According to PTC Therapeutics Inc [NASDAQ:PTCT], the company’s sales were 937.82M for trailing twelve months, which represents an 83.41% jump. Gross Profit Margin for this corporation currently stands at 0.85% with Operating Profit Margin at -0.47%, Pretax Profit Margin comes in at -0.74%, and Net Profit Margin reading is -0.67%. To continue investigating profitability, this company’s Return on Assets is posted at -0.33, Equity is 0.99 and Total Capital is -0.34. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -0.37.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 24.44 points at the first support level, and at 23.39 for the second support level. However, for the 1st resistance point, the stock is sitting at 26.09, and for the 2nd resistance point, it is at 26.70.
Ratios To Look Out For
It is important to note that PTC Therapeutics Inc [NASDAQ:PTCT] has a current ratio of 2.02. Further, the Quick Ratio stands at 1.97, while the Cash Ratio is 0.98. Considering the valuation of this stock, the price to sales ratio is 2.08.
Transactions by insiders
Recent insider trading involved Klein Matthew B., CHIEF EXECUTIVE OFFICER, that happened on Apr 19 ’24 when 3361.0 shares were sold. CHIEF EXECUTIVE OFFICER, Klein Matthew B. completed a deal on Apr 17 ’24 to sell 1307.0 shares. Meanwhile, CHIEF EXECUTIVE OFFICER Pauwels Eric sold 787.0 shares on Apr 17 ’24.
